Ieq Capital LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 98,429 shares of the company’s stock, valued at approximately $780,000. Ieq Capital LLC owned 0.06% of Xeris Biopharma as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new position in Xeris Biopharma in the 2nd quarter worth about $115,042,000. Vanguard Group Inc. increased its position in shares of Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares in the last quarter. State Street Corp raised its holdings in shares of Xeris Biopharma by 10.1% during the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after acquiring an additional 378,595 shares during the period. Finally, Qube Research & Technologies Ltd raised its holdings in shares of Xeris Biopharma by 6.0% during the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after acquiring an additional 185,063 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on XERS shares. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Barclays increased their target price on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xeris Biopharma has a consensus rating of “Hold” and an average price target of $12.00.
Insider Buying and Selling
In other Xeris Biopharma news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00. Following the completion of the sale, the insider owned 1,361,053 shares of the company’s stock, valued at $11,568,950.50. This trade represents a 0.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.01, for a total transaction of $133,494.66. Following the transaction, the insider owned 1,144,462 shares in the company, valued at approximately $9,167,140.62. This represents a 1.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 271,499 shares of company stock worth $2,038,917. Insiders own 4.35% of the company’s stock.
Xeris Biopharma Price Performance
Shares of XERS opened at $8.60 on Friday. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -78.18 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The business’s 50-day moving average is $8.26 and its 200-day moving average is $6.92.
Xeris Biopharma (NASDAQ:XERS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.
Xeris Biopharma Profile
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
Featured Stories
- Five stocks we like better than Xeris Biopharma
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
